ArticleFrontiers in oncology2026
Identification and validation of prognostic genes associated with clear cell renal cell carcinoma: based on public whole transcriptome sequencing datasets.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is a prevalent malignancy, representing 80-90% of kidney cancer cases. This study aimed to identify potential prognostic genes to improve patient survival prediction and provide new insights into the pathogenesis and treatment of ccRCC through comprehensive whole transcriptome sequencing analysis. Methods: The analysis utilized whole transcriptomic data from publicly available datasets, including TCGA-KIRC and GSE96574. Methods involved identifying differentially expressed mRNAs and long non-coding RNAs, prognostic gene screening via MCODE plugin and risk model construction, followed by functional enrichment, molecular network construction, drug prediction, and molecular docking. The expression levels of key genes were subsequently validated using reverse transcription quantitative PCR (RT-qPCR) on clinical samples. Results: Eight prognostic genes (IFNG, CXCL13, KLRK1, LAG3, ITGAX, TNFRSF9, CD2, CD8B) were identified and formed a risk stratification model. These genes were primarily enriched in immune-related pathways such as antigen processing and presentation. A regulatory network involving transcription factors, miRNAs, lncRNA PVT1, and circRNAs was constructed. Drug prediction and molecular docking suggested potential targeted drugs, including amitriptyline hydrochloride for CD8B and IFNG, and rituximab for CXCL13 and IFNG, with strong binding affinities noted for ITGAX and KLRK1. RT-qPCR validation confirmed significantly elevated expression of IFNG, LAG3, TNFRSF9, and CD8B in ccRCC patients compared to controls (p < 0.05). Conclusions: This study identifies an eight-gene signature as a promising prognostic biomarker for ccRCC, deeply involved in the tumor immune microenvironment. The findings offer novel insights into ccRCC pathogenesis and highlight potential therapeutic targets and agents, paving the way for improved prognostic strategies and immunotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.